A phase I trial of the oral cyclin dependent kinase inhibitor CYC202 in patients with advanced malignancy

被引：0
|
作者：
White, JD
Cassidy, J
Twelves, C
Benson, C
Pacey, S
Judson, I
McGrath, H
Rose, F
Frenz, L
机构：
[1] Western Infirm & Associated Hosp, Beatson Oncol Ctr, Glasgow G11 6NT, Lanark, Scotland
[2] Royal Marsden Hosp, RMH, Sutton, Surrey, England
[3] Canc Res UK, London, England
[4] Cyclacel Ltd, Dundee, Scotland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3042
引用
收藏
页码：205S / 205S
页数：1
相关论文
共 50 条
  • [1] A Phase I and pharmacokinetic (PK) trial of CYC202, a novel oral cyclin-dependent kinase (CDK) inhibitor, in patients with advanced solid tumors: Exploration of three administration schedules.
    Faivre, S
    Pierga, JY
    Delbaldo, C
    Laurence, V
    Vera, K
    Bekradda, M
    Armand, JP
    Gianella-Borradori, A
    Dieras, V
    Girre, V
    Raymond, E
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6107S - 6107S
  • [2] Preliminary results of an ongoing phase I and pharmacokinetic study of CYC202, a novel oral cyclin-dependent kinases inhibitor, in patients with advanced malignancies
    Laurence, V
    Faivre, S
    Vera, K
    Pierga, J
    Delbaldo, C
    Bekradda, M
    Armand, J
    Gianella-Borradori, A
    Dieras, V
    Raymond, E
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S49 - S49
  • [3] Reversal of collapsing glomerulopathy in mice with the cyclin-dependent kinase inhibitor CYC202
    Gherardi, D
    D'Agati, V
    Chu, THT
    Barnett, A
    Gianella-Borradori, A
    Gelman, IH
    Nelson, PJ
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2004, 15 (05): : 1212 - 1222
  • [4] Gene expression profiling of the cyclin-dependent kinase inhibitor CYC202 (R-Roscovitine)
    Whittaker, SR
    Te Poele, R
    Walton, MI
    Garrett, MD
    Workman, P
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S50 - S50
  • [5] In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine)
    McClue, SJ
    Blake, D
    Clarke, R
    Cowan, A
    Cummings, L
    Fischer, PM
    MacKenzie, M
    Melville, J
    Stewart, K
    Wang, SD
    Zhelev, N
    Zheleva, D
    Lane, DP
    INTERNATIONAL JOURNAL OF CANCER, 2002, 102 (05) : 463 - 468
  • [6] A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days
    C Benson
    J White
    J De Bono
    A O'Donnell
    F Raynaud
    C Cruickshank
    H McGrath
    M Walton
    P Workman
    S Kaye
    J Cassidy
    A Gianella-Borradori
    I Judson
    C Twelves
    British Journal of Cancer, 2007, 96 : 29 - 37
  • [7] A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days
    Benson, C.
    White, J.
    De Bono, J.
    O'Donnell, A.
    Raynaud, F.
    Cruickshank, C.
    McGrath, H.
    Walton, M.
    Workman, P.
    Kaye, S.
    Cassidy, J.
    Gianella-Borradori, A.
    Judson, I.
    Twelves, C.
    BRITISH JOURNAL OF CANCER, 2007, 96 (01) : 29 - 37
  • [8] The cyclin-dependent kinase inhibitor cyc202 is effective in human leiomyosarcoma (LMS) cell lines in combination with doxorubicin
    Coley, HM
    Shotton, CS
    Thomas, H
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S111 - S111
  • [9] Effects of the cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) on the physiology of cultured human keratinocytes
    Atanasova, G
    Jans, R
    Zhelev, N
    Mitev, V
    Poumay, Y
    BIOCHEMICAL PHARMACOLOGY, 2005, 70 (06) : 824 - 836
  • [10] In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphoma
    Lacrima, K
    Valentini, A
    Lambertini, C
    Taborelli, M
    Rinaldi, A
    Zucca, E
    Catapano, C
    Cavalli, F
    Gianella-Borradori, A
    MacCallum, DE
    Bertoni, F
    ANNALS OF ONCOLOGY, 2005, 16 (07) : 1169 - 1176
12345